AGP Picks
View all

Nepal Healthcare Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.

Press releases published on August 12, 2026

Kura Oncology Reports Second Quarter 2026 Financial Results
Acquisition of Own Shares
Inkoop van eigen aandelen
Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Earth Science Tech, Inc. (ETST) Expands National Footprint with Strategic Acquisition of California Compounding Pharmacy, Meduvo LLC
Rampart zieht Berufung gegen Ungültigkeitsentscheidung des USPTO zurück
Rampart retira su apelación de la decisión de invalidación de la USPTO
Rampart retire son recours contre la décision d’invalidation de l’USPTO
חברת Rampart משכה את הערעור על החלטת ה-USPTO לפסול את תוקף הפטנט
Rampart Mencabut Banding atas Keputusan USPTO yang Membatalkan Keabsahan Paten
ランパート、米国特許商標庁の無効決定に対する上訴を取り下げる
Rampart, 미국 특허상표청의 특허 무효 결정에 대한 항소 철회
Rampart Menarik Balik Rayuan terhadap Keputusan USPTO yang Mengisytiharkan Paten Tidak Sah
Rampart Retira Recurso da Decisão de Invalidação do USPTO
Rampart ถอนอุทธรณ์คำตัดสินของ USPTO ที่สั่งให้สิทธิบัตรเป็นโมฆะ

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Nepal Healthcare Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.